NCT05652283 2024-11-27
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT03427814 2024-10-26
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
BeiGene
Phase 2 Completed
NCT03575065 2024-10-26
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
BeiGene
Phase 2 Completed
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT05489926 2024-01-26
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04985721 2023-03-15
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05376722 2023-01-05
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05669768 2023-01-03
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
Phase 2 Unknown
NCT05483543 2022-08-02
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
Fudan University
Phase 2 Unknown
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT05327621 2022-04-14
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT03712930 2021-11-17
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
BeiGene
Phase 2 Terminated
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn